Anti-TNF-alpha therapy rapidly proved to be an efficacious, albeit expensive, treatment for other immune-mediated inflammatory diseases (IMIDs), such as refractory rheumatoid arthritis (RA), ankylosing spondylitis (SpA) and psoriasis (1–3). This evidence concerns the gene TNF and rheumatoid arthritis.